242 related articles for article (PubMed ID: 19782085)
1. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.
Dore GJ; Hellard M; Matthews GV; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan G; White P; French R; Rawlinson W; Lloyd AR; Kaldor JM;
Gastroenterology; 2010 Jan; 138(1):123-35.e1-2. PubMed ID: 19782085
[TBL] [Abstract][Full Text] [Related]
2. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
Carriero D; Fabrizi F; Uriel AJ; Park J; Martin P; Dieterich DT
Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584
[TBL] [Abstract][Full Text] [Related]
3. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
[TBL] [Abstract][Full Text] [Related]
7. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
Reddy KR; Shiffman ML; Rodriguez-Torres M; Cheinquer H; Abdurakhmanov D; Bakulin I; Morozov V; Silva GF; Geyvandova N; Stanciu C; Rabbia M; McKenna M; Thommes JA; Harrison SA;
Gastroenterology; 2010 Dec; 139(6):1972-83. PubMed ID: 20816836
[TBL] [Abstract][Full Text] [Related]
8. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Berg T; von Wagner M; Nasser S; Sarrazin C; Heintges T; Gerlach T; Buggisch P; Goeser T; Rasenack J; Pape GR; Schmidt WE; Kallinowski B; Klinker H; Spengler U; Martus P; Alshuth U; Zeuzem S
Gastroenterology; 2006 Apr; 130(4):1086-97. PubMed ID: 16618403
[TBL] [Abstract][Full Text] [Related]
9. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
[TBL] [Abstract][Full Text] [Related]
10. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
11. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
12. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
[TBL] [Abstract][Full Text] [Related]
13. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
[TBL] [Abstract][Full Text] [Related]
15. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals.
Hopkins S; Lambourne J; Farrell G; McCullagh L; Hennessy M; Clarke S; Mulcahy F; Bergin C
HIV Med; 2006 May; 7(4):248-54. PubMed ID: 16630037
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
Parise E; Cheinquer H; Crespo D; Meirelles A; Martinelli A; Sette H; Gallizi J; Silva R; Lacet C; Correa E; Cotrim H; Fonseca J; Paraná R; Spinelli V; Amorim W; Tatsch F; Pessoa M;
Braz J Infect Dis; 2006 Feb; 10(1):11-6. PubMed ID: 16767309
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response.
El Khayat HR; Fouad YM; El Amin H; Rizk A
Trop Gastroenterol; 2012; 33(2):112-7. PubMed ID: 23025057
[TBL] [Abstract][Full Text] [Related]
20. Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.
Martinello M; Hellard M; Shaw D; Petoumenos K; Applegate T; Grebely J; Yeung B; Maire L; Iser D; Lloyd A; Thompson A; Sasadeusz J; Haber P; Dore GJ; Matthews GV
Antivir Ther; 2016; 21(5):425-34. PubMed ID: 26867206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
